| Name | Title | Contact Details |
|---|
MicroConstants is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio`s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need,
We firmly believe in the integration of science research and traditional wisdom as the way that nutritional and herbal supplements will reach their exciting potential. Founded in 1990 by a pioneering physician committed to science-based alternative health care, Doctor’s Best offers only the most important nutritional supplements. Careful research and precise formula development keeps us at the leading edge of quality, effectiveness, and innovation. Containing the finest quality raw materials from around the world, Doctor’s Best supplements embody the best that traditional knowledge and current scientific research have to offer in the field of therapeutic nutrition. Countless hours have been spent analyzing scientific literature to provide sound alternatives to the proliferation of questionable supplements in the marketplace. Each of our products is accompanied by an annotated ""Fact Sheet"" with detailed background information, structure-function statements, and scientific references that substantiate these statements. All structure-function statements have been filed with FDA in accordance with DSHEA regulations.
Dechra Pharmaceuticals PLC is a global leader in veterinary pharmaceuticals, dedicated exclusively to the veterinary market. Founded in 1997, the company has a rich history dating back to 1819. Dechra develops, manufactures, and markets high-quality pharmaceutical products and services aimed at improving animal health and welfare. It operates in 24 countries and distributes products in over 50 countries. The company offers a diverse portfolio of prescription-only veterinary medicines for companion animals and horses, focusing on areas such as endocrinology, dermatology, and critical care. Dechra also provides water-soluble antibiotics, poultry vaccines, and specialized diets. Its services division includes laboratories that support veterinary diagnostics. With a strong emphasis on understanding veterinarians needs, Dechra provides training and scientific resources to enhance animal care.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that affect a significant number of patients globally. The Company has four product candidates in development that address viral infections that have limited therapeutic options. We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 and 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial.